For your patients today and tomorrow

Johnson & Johnson broad portfolio of immunotherapies is leading the way

With 5 options across multiple lines of therapy, Johnson & Johnson is focused on helping you manage your patients

First anti-CD38 mAb;
administered as intravenous infusion¹

First and only combination
of anti-CD38 mAb and
hyaluronidase-fihj; given as
a subcutaneous injection²

DISCOVER MORE

BCMA-directed CAR-T therapy;
delivered as a single infusion³^*

*Although delivered as a single infusion, therapy with CARVYKTI® is part of a
multi-step process.³DISCOVER MORE

First-in-class BCMAxCD3-directed
bispecific antibody; given as
a subcutaneous injection^4,5

DISCOVER MORE

First-in-class GPRC5DxCD3-
directed bispecific antibody; given
as a subcutaneous injection^6,7

DISCOVER MORE

BCMA=B-cell maturation antigen; CAR-T=chimeric antigen receptor-T cell; CD3=cluster of differentiation 3; CD38=cluster of differentiation 38; GPRC5D=G-protein-coupled receptor, class C, group 5, member D; mAb=monoclonal antibody.Strategic partnerships and collaborations: CARVYKTI®: Legend Biotech.BCMA=B-cell maturation antigen; CAR-T=chimeric antigen receptor-T cell;
CD3=cluster of differentiation 3; CD38=cluster of differentiation 38;
GPRC5D=G-protein-coupled receptor, class C, group 5, member D; mAb=monoclonal antibody.Strategic partnerships and collaborations: CARVYKTI®: Legend Biotech.